Inositol, neural tube closure and the prevention of neural tube defects.
Susceptibility to neural tube defects (NTDs), such as anencephaly and spina bifida is influenced by genetic and environmental factors including maternal nutrition. Maternal periconceptional supplementation with folic acid significantly reduces the risk of an NTD-affected pregnancy, but does not prevent all NTDs, and "folic acid non-responsive" NTDs continue to occur. Similarly, among mouse models of NTDs, some are responsive to folic acid but others are not. Among nutritional factors, inositol deficiency causes cranial NTDs in mice while supplemental inositol prevents spinal and cranial NTDs in the curly tail (Grhl3 hypomorph) mouse, rodent models of hyperglycemia or induced diabetes, and in a folate-deficiency induced NTD model. NTDs also occur in mice lacking expression of certain inositol kinases. Inositol-containing phospholipids (phosphoinositides) and soluble inositol phosphates mediate a range of functions, including intracellular signaling, interaction with cytoskeletal proteins, and regulation of membrane identity in trafficking and cell division. Myo-inositol has been trialed in humans for a range of conditions and appears safe for use in human pregnancy. In pilot studies in Italy and the United Kingdom, women took inositol together with folic acid preconceptionally, after one or more previous NTD-affected pregnancies. In nonrandomized cohorts and a randomized double-blind study in the United Kingdom, no recurrent NTDs were observed among 52 pregnancies reported to date. Larger-scale fully powered trials are needed to determine whether supplementation with inositol and folic acid would more effectively prevent NTDs than folic acid alone. Birth Defects Research 109:68-80, 2017. © 2016 The Authors Birth Defects Research Published by Wiley Periodicals, Inc.
Newlife Birth Defects Research Centre and Developmental Biology & Cancer Programme, Institute of Child Health, University College London, London, United Kingdom.
Nicholas D E
ND
Greene
Newlife Birth Defects Research Centre and Developmental Biology & Cancer Programme, Institute of Child Health, University College London, London, United Kingdom.
Kit-Yi
KY
Leung
Newlife Birth Defects Research Centre and Developmental Biology & Cancer Programme, Institute of Child Health, University College London, London, United Kingdom.
Andrew J
AJ
Copp
D000818:Animals; D002986:Clinical Trials as Topic; D019587:Dietary Supplements; D004195:Disease Models, Animal; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D005494:Folic Acid Deficiency / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007294:Inositol / Q000008:administration & dosage*; D007295:Inositol Phosphates / Q000378:metabolism; D039382:Maternal Nutritional Physiological Phenomena; D051379:Mice; D054259:Neural Tube / Q000002:abnormalities / Q000187:drug effects* / Q000378:metabolism; D009436:Neural Tube Defects / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D010716:Phosphatidylinositols / Q000378:metabolism; D011247:Pregnancy
D007295:Inositol Phosphates; D010716:Phosphatidylinositols; D007294:Inositol; D005492:Folic Acid
clinical trial; folic acid; inositol; neural tube defects; phosphoinositide; spina bifida